<?xml version="1.0" encoding="UTF-8"?>
<ref id="B57-jcm-09-02084">
 <label>57.</label>
 <element-citation publication-type="web">
  <person-group person-group-type="author">
   <collab>Gilead</collab>
  </person-group>
  <article-title>Gilead Announces Results from Phase 3 Trial of Investigational Antiviral Remdesivir in Patients with Severe COVID-19</article-title>
  <comment>Available online: 
   <ext-link ext-link-type="uri" xlink:href="https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19</ext-link>
  </comment>
  <date-in-citation content-type="access-date" iso-8601-date="2020-04-30">(accessed on 30 April 2020)</date-in-citation>
 </element-citation>
</ref>
